Oncology

Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.

Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations.

This is the fourth approval for Jakafi, a JAK1/JAK2 inhibitor.

Keytruda plus chemotherapy reduces the risk of death by 27% in patients with triple-negative breast cancer.

A recent City of Hope study claims a therapy that combines a drug that disrupts DNA repair with chemotherapy cisplatin and gemcitabine does not prolong progression-free survival for patients with urothelial cancer.

Tivdak is the first approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer.

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 19, 2022.

The approval comes more than two months ahead of its PDUFA target date of December 4, 2021.

Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations. This is the second approval for this mutation and the first oral therapy.

Real-world data show Erleada prolonged survival in both metastatic and non-metastatic castration-sensitive prostate cancer.

The approval follows the FDA’s Oncologic Drugs Advisory Committee voting 5-3 in favor of maintaining the approval despite a confirmatory trial that found Keytruda did not meet the end points of overall survival and progression-free survival.

Mobile devices for patients to report symptoms associated with immune checkpoint inhibitors address an unmet need.

Tecentriq loses indication, Xarelto is approved for reduce risks of cardiovascular events, Tibsovo is approved for rare cancer, Skytrofa is a new, once-weekly growth hormone, and supplemental application is filed Orencia graft-versus-host disease.

Tecentriq did not meet the primary end point in a postmarketing study as a first-line treatment.

Tibsovo is the first targeted therapy for IDH1-mutated cholangiocarcinoma, a cancer of the bile ducts within and outside the liver.

Study results reported in JAMA Network Open show that financial incentives are only modestly effective in getting more people to get way screened for colorectal cancer.

The FDA has set a PDUFA date of December 23, 2021.

FDA approves Opdivo, Jardiance for new indication, Jemperli gets accelerated approval for solid tumors, and Lilly’s rapid-acting insulin, Lyumjev is approved for administration via an insulin pump.

The therapy is the first approved for patients with tumors associated with von Hippel-Lindau disease.

The therapy is expected to be available by early September.

Libtayo also reduced the risk of death by 29% compared with chemotherapy alone.

The graft-versus-host disease therapy has also been added to NCCN Guidelines.

The PDUFA date has been set for December 4, 2021; FDA has designated this as a Priority Review.

The PDUFA date for this indication is December 4, 2021.

The FDA is expected to make a decision on this indication by December 1, 2021.